Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Federica Lo Prinzi, Margherita Rimini, Masafumi Ikeda, Oluseyi Abidoye et autres
it, jp, us, kr, de, gb, au, ps, pt, es, by, at, tw, hk, cn, ca (code pays fourni par la source)